Compare Nuwellis Inc (NUWE) vs Old National Bancorp Common Stock (ONB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Old National Bancorp Common Stock — how do they compare? Nuwellis Inc trades at $0.53 (market cap $2.00M), while Old National Bancorp Common Stock trades at $24.48 (market cap $9.42B). The key difference: Old National Bancorp Common Stock is far larger — about 4710× Nuwellis Inc's market cap, and Old National Bancorp Common Stock pays a 2.36% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 27 Days and Old National Bancorp Common Stock for 0 Days on average.
| NUWE | ONB | |
|---|---|---|
Market Cap | $2.00M | $9.42B |
Volume | 172,259 | 4,606,260 |
Sector | Health | Financials |
52-Week High | $146.65 | $27.29 |
52-Week Low | $0.53 | $19.60 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | -$1.72M | $16.07B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.621, down 7.35% today, with a bearish technical signal despite oversold RSI readings. The company shows revenue growth with 2026 revenue reaching $9M, but continues to post significant losses with a -125.63% net income margin. Recent positive developments include strong Aquadex console adoption and expanded pediatric footprint, though cash flow remains negative requiring ongoing financing.
The outlook remains challenging with persistent losses and negative cash flow offset by promising commercial momentum. Investment opportunity hinges on the company's ability to achieve profitability while risks include execution challenges and dependence on financing. Analyst sentiment is mixed with equal buy/hold ratings reflecting the high-risk, high-reward nature of this medical technology stock.
ONB trades at $24.62, down 0.73% on the day, with a neutral technical outlook and key support at $24. The company shows strong fundamentals, with a P/E of 10.89 and net income margin of 31.39%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights upcoming Q3 earnings and positive institutional investment activity.
The outlook for ONB is positive, supported by robust earnings growth and a 'Buy' consensus from analysts with a $29.67 price target. Key risks include potential earnings volatility and macroeconomic pressures on the banking sector. Upside potential exists if the company continues its trend of exceeding earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Old National Bancorp Common Stock
Old National Bancorp is the bank holding company for Old National Bank, providing consumer banking, commercial banking, wealth management, and capital markets services across Indiana, Kentucky, Michigan, Minnesota, and Wisconsin.
Read more on ONB →
